⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CADL News
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
CADL
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
globenewswire.com
CADL
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
globenewswire.com
CADL
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
globenewswire.com
CADL
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
prnewswire.com
TRIN
CADL
TRIN
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
globenewswire.com
CADL
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
globenewswire.com
CADL
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
globenewswire.com
CADL
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
globenewswire.com
CADL